secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001104659-24-039341
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar reports FY2023 net loss $38M; plans iopofosine NDA submission H2 2024
-------------------------------------------------------------------------------

- Net loss $38.0M ($3.11 per share) vs $28.6M ($4.05) in prior year.
- Cash $9.6M at Dec 31, 2023; plus $44.1M from Jan 2024 warrant exercise funds into Q4 2024.
- CLOVER WaM study met primary endpoint: MRR 61%, ORR 75.6%, 7.3% CR in refractory WM.
- R&D expense $28.2M, up 47% YoY, driven by manufacturing for trials and commercial readiness.
- Positive topline data announced; NDA submission planned H2 2024 with request for accelerated approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924039341/0001104659-24-039341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924039341/tm249908d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-039341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer